About The Clorox (NYSE:CLX)
The Clorox Company is a manufacturer and marketer of consumer and professional products. The Company sells its products primarily through mass retail outlets, e-commerce channels, wholesale distributors and medical supply distributors. The Company operates through four segments: Cleaning, Household, Lifestyle and International. Its Cleaning segment consists of laundry, home care and professional products marketed and sold in the United States. Its Household segment consists of charcoal, cat litter and plastic bags, wraps and container products marketed and sold in the United States. Its Lifestyle segment consists of food products, water-filtration systems and filters, and natural personal care products marketed and sold in the United States. Its International segment consists of products sold outside the United States. It markets some of the consumer brand names, such as namesake bleach and cleaning products, Pine-Sol cleaners, Liquid-Plumr clog removers and Kingsford charcoal.
Industry, Sector and Symbol
Trailing P/E Ratio21.1419490791239
Forward P/E Ratio20.63
Sales & Book Value
Annual Sales$5.97 billion
Price / Sales2.78
Cash Flow$6.70 per share
Price / Cash19.11
Book Value$4.21 per share
Price / Book30.43
Net Income$701 million
Return on Equity126.70%
Return on Assets15.69%
The Clorox (NYSE:CLX) Frequently Asked Questions
What is The Clorox's stock symbol?
The Clorox trades on the New York Stock Exchange (NYSE) under the ticker symbol "CLX."
How often does The Clorox pay dividends? What is the dividend yield for The Clorox?
The Clorox announced a quarterly dividend on Tuesday, February 13th. Shareholders of record on Wednesday, April 25th will be paid a dividend of $0.96 per share on Friday, May 11th. This represents a $3.84 dividend on an annualized basis and a yield of 3.00%. The ex-dividend date is Tuesday, April 24th. This is a boost from The Clorox's previous quarterly dividend of $0.84. View The Clorox's Dividend History.
How were The Clorox's earnings last quarter?
The Clorox Company (NYSE:CLX) released its earnings results on Friday, February, 2nd. The company reported $1.23 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $1.22 by $0.01. The firm had revenue of $1.42 billion for the quarter, compared to analysts' expectations of $1.43 billion. The Clorox had a return on equity of 126.70% and a net margin of 13.21%. The Clorox's quarterly revenue was up .7% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.14 earnings per share. View The Clorox's Earnings History.
When will The Clorox make its next earnings announcement?
What guidance has The Clorox issued on next quarter's earnings?
The Clorox updated its FY18 earnings guidance on Friday, February, 2nd. The company provided earnings per share guidance of $6.17-6.37 for the period, compared to the Thomson Reuters consensus EPS estimate of $5.66. The company issued revenue guidance of +1-3% to ~$6.03-6.15 billion, compared to the consensus revenue estimate of $6.13 billion.
Where is The Clorox's stock going? Where will The Clorox's stock price be in 2018?
12 brokerages have issued 12 month price targets for The Clorox's shares. Their predictions range from $76.00 to $148.00. On average, they expect The Clorox's stock price to reach $131.62 in the next year. View Analyst Ratings for The Clorox.
What are Wall Street analysts saying about The Clorox stock?
Here are some recent quotes from research analysts about The Clorox stock:
- 1. According to Zacks Investment Research, "Clorox delivered better-than-expected second-quarter fiscal 2018 earnings, which also marked its fifth straight earnings beat. Results gained from solid sales and lower tax rate. Sales improved year over year driven by strength in International, Lifestyle and Cleaning segments due to higher prices. Moreover, the company’s 2020 Strategy, aimed at bolstering growth for the improvement of categories and overall market share, bodes well. Moreover, the company reiterated sales guidance for fiscal 2018, while it raised the earnings view to include the benefits of the new tax reform. However, Clorox lagged the industry in the past month. The company witnessed significant pressure on gross margin in the second quarter owing to elevated input costs for commodities and tightening of transportation market, which are likely to continue hurting margins in fiscal 2018. Nonetheless, its approach to brand management and Go Lean strategy are noteworthy." (2/6/2018)
- 2. Wells Fargo analysts commented, "We maintain our Market Perform rating. CLX Is Among The Best Positioned In Our Broader Staples Coverage Universe To Benefit From U.S. Tax Reform – Our detailed analysis of the pot’l reforms across broader Staples indicates that this could generate ~+20% EPS accretion for CLX if lowered from 35% to ~20%. We estimate that up to ~55% of this potential upside from pot’l corporate tax reform is currently priced into shares, implying further upside potential for CLX shares (possibly to ~$155-160/shr) if reforms are implemented. (For details on our quantification, please see p. 4). Continued Confidence in CLX’s FY18 Growth Outlook – Management reiterated its 1-3% FY18 sales growth guidance (we continue to estimate +2.3%). Sales growth is still likely to sequentially moderate in F2Q vs. FQ1 due to: (1) Tougher y/y comparisons; (2) A reversal of hurricane-related sales pull-forward; and (3) A slowdown in the Wipes business as CLX takes pricing." (12/13/2017)
- 3. Jefferies Group LLC analysts commented, "In what has been a challenging earnings season in HPC/beverages, CLX’s 1Q print was strong w/org sales upside (4% vs. Street ~3%) and better than expected margins driving a 4-cent EPS beat ($1.46 vs. $1.42). CLX trimmed its FY18 EPS guidance by less than 1% to $5.47-$5.67 (vs. Street/JEF $5.64/$5.55), which was likely not as bad as feared (> 2% cut). Valuation still looks full at 22.5x EV/ULFCF, though we’d expect a positive reaction on the print. Solid start to FY18 with high-quality 1Q EPS beat: Reported 1Q revs of $1.50B were 1 pt ahead of consensus as ~4% org sales growth was above Street estimates of +2.9%. Gross margins of 44.9% came in 25 bps above Street est., driving a >1.5% gross profit beat. SG&A was in-line at 24.7% of sales with OI 2.5% ahead of Consensus. Below the line items (lower tax rate and share count partially offset by a modest other income drag) were a $0.02 net benefit vs. our model as EPS of $1.46 beat Street est. by $0.04 on generally good quality." (11/1/2017)
Who are some of The Clorox's key competitors?
Some companies that are related to The Clorox include HENKEL AG&CO. KGAA (HENKY), Shiseido (SSDOY), Coty (COTY), Church & Dwight (CHD), Nu Skin Enterprises (NUS), Helen of Troy (HELE), Inter Parfums (IPAR), Revlon (REV), Avon Products (AVP), e.l.f. Beauty (ELF), Divine skin. (DSKX) and Symrise (SYIEY).
Who are The Clorox's key executives?
The Clorox's management team includes the folowing people:
- Benno O. Dorer, Chairman of the Board, Chief Executive Officer
- Stephen M. Robb, Chief Financial Officer, Executive Vice President
- Dawn C. Willoughby, Chief Operating Officer, Executive Vice President
- Laura Stein J.D., Executive Vice President, General Counsel - Corporate Affairs
- Manjit Singh, Senior Vice President, Chief Information Officer
- Eric H. Reynolds, Senior Vice President, Chief Marketing Officer
- Jon M. Balousek, Senior Vice President, General Manager - Specialty Division
- Linda Rendle, Senior Vice President, General Manager - Cleaning Division
- William S. Bailey, Senior Vice President – Corporate Business Development
- Michael R. Costello, Senior Vice President - International
Has The Clorox been receiving favorable news coverage?
Press coverage about CLX stock has trended somewhat positive on Tuesday, Accern Sentiment Analysis reports. The research firm ranks the sentiment of press coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. The Clorox earned a news sentiment score of 0.13 on Accern's scale. They also gave news articles about the company an impact score of 43.88 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the next several days.
Who are The Clorox's major shareholders?
The Clorox's stock is owned by a variety of of retail and institutional investors. Top institutional investors include BlackRock Inc. (7.89%), Parnassus Investments CA (3.44%), Wells Fargo & Company MN (3.33%), Cedar Rock Capital Ltd. (1.91%), Renaissance Technologies LLC (1.82%) and APG Asset Management N.V. (1.40%). Company insiders that own The Clorox stock include A D David Mackay, Dawn C Willoughby, James E Foster, Jon M Balousek, Laura Stein, Matthew T Laszlo, Michael R Costello and Nikolaos A Vlahos. View Institutional Ownership Trends for The Clorox.
Which major investors are selling The Clorox stock?
CLX stock was sold by a variety of institutional investors in the last quarter, including KAMES CAPITAL plc, Bank of Montreal Can, Gotham Asset Management LLC, Millennium Management LLC, KBC Group NV, WINTON GROUP Ltd, Shell Asset Management Co. and Wells Fargo & Company MN. Company insiders that have sold The Clorox company stock in the last year include Dawn C Willoughby, James E Foster, Jon M Balousek, Matthew T Laszlo and Michael R Costello. View Insider Buying and Selling for The Clorox.
Which major investors are buying The Clorox stock?
CLX stock was purchased by a variety of institutional investors in the last quarter, including Two Sigma Advisers LP, APG Asset Management N.V., Renaissance Technologies LLC, Schroder Investment Management Group, Amundi Pioneer Asset Management Inc., Acadian Asset Management LLC, Nuance Investments LLC and Bank of New York Mellon Corp. View Insider Buying and Selling for The Clorox.
How do I buy shares of The Clorox?
Shares of CLX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is The Clorox's stock price today?
One share of CLX stock can currently be purchased for approximately $128.12.
How big of a company is The Clorox?
The Clorox has a market capitalization of $16.63 billion and generates $5.97 billion in revenue each year. The company earns $701 million in net income (profit) each year or $6.06 on an earnings per share basis. The Clorox employs 8,100 workers across the globe.
How can I contact The Clorox?
The Clorox's mailing address is 1221 BROADWAY, OAKLAND CA, 94612. The company can be reached via phone at 510-271-7000 or via email at [email protected]
MarketBeat Community Rating for The Clorox (CLX)MarketBeat's community ratings are surveys of what our community members think about The Clorox and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
The Clorox (NYSE:CLX) Analysts' Consensus Rating (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Today||30 Days Ago||90 Days Ago||180 Days Ago|
|Consensus Rating: ||Hold||Hold||Hold||Hold|
|Consensus Rating Score: ||2.17||2.17||2.18||2.10|
|Ratings Breakdown: ||0 Sell Rating(s)|
10 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
10 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
9 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
9 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
|Consensus Price Target: ||$131.62||$131.53||$126.80||$124.89|
|Price Target Upside: ||2.73% upside||2.90% upside||13.51% downside||7.51% downside|
The Clorox (NYSE:CLX) Consensus Price Target History
The Clorox (NYSE:CLX) Analyst Ratings History
(Data available from 3/20/2016 forward)
The Clorox (NYSE:CLX) Earnings History and Estimates Chart
The Clorox (NYSE CLX) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|2/2/2018||Q2 2018||$1.22||$1.23||$1.43 billion||$1.42 billion||View||Listen|
|11/1/2017||Q1 2018||$1.41||$1.46||$1.48 billion||$1.50 billion||View||N/A|
|8/3/2017||Q4 2017||$1.49||$1.53||$1.65 billion||$1.65 billion||View||Listen|
|5/3/2017||Q3 2017||$1.30||$1.31||$1.48 billion||$1.48 billion||View||Listen|
|2/3/2017||Q217||$1.22||$1.25||$1.41 billion||$1.41 billion||View||N/A|
|11/2/2016||Q117||$1.42||$1.36||$1.24 billion||$1.44 billion||View||N/A|
|8/3/2016||Q416||$1.28||$1.26||$1.58 billion||$1.60 billion||View||Listen|
|5/3/2016||Q316||$1.11||$1.21||$1.41 billion||$1.43 billion||View||N/A|
|2/4/2016||Q216||$1.05||$1.14||$1.35 billion||$1.35 billion||View||Listen|
|11/2/2015||Q116||$1.18||$1.32||$1.37 billion||$1.39 billion||View||Listen|
|8/3/2015||Q415||$1.37||$1.44||$1.52 billion||$1.56 billion||View||N/A|
|5/1/2015||Q315||$1.10||$1.08||$1.38 billion||$1.40 billion||View||Listen|
|2/4/2015||Q215||$0.90||$0.97||$1.30 billion||$1.35 billion||View||Listen|
|10/31/2014||Q115||$1.03||$1.10||$1.33 billion||$1.35 billion||View||Listen|
|8/1/2014||Q4||$1.34||$1.40||$1.52 billion||$1.51 billion||View||Listen|
|5/1/2014||Q314||$1.08||$1.18||$1.43 billion||$1.39 billion||View||N/A|
|2/4/2014||Q214||$0.91||$0.88||$1.31 billion||$1.33 billion||View||N/A|
|10/31/2013||Q114||$1.01||$1.04||$1.35 billion||$1.36 billion||View||N/A|
|8/1/2013||Q4 2013||$1.34||$1.38||$1.57 billion||$1.55 billion||View||N/A|
|5/1/2013||Q3 2013||$1.06||$1.00||$1.44 billion||$1.41 billion||View||N/A|
|2/4/2013||Q2 2013||$0.80||$0.90||$1.27 billion||$1.33 billion||View||N/A|
|10/31/2012||Q113||$0.95||$1.01||$1.35 billion||$1.34 billion||View||N/A|
The Clorox (NYSE:CLX) Earnings Estimates
2018 EPS Consensus Estimate: $5.63
2019 EPS Consensus Estimate: $6.59
(Earnings estimates data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
The Clorox (NYSE:CLX) Dividend Information
|Dividend Growth:||4.20% (3 Year Average)|
|Payout Ratio:||55.45% (Trailing 12 Months of Earnings) |
54.11% (Based on This Year's Estimates)
51.53% (Based on Next Year's Estimates)
|Track Record:||40 Years of Consecutive Dividend Growth|
The Clorox (NYSE:CLX) Dividend History by Quarter
(Data available from 1/1/2013 forward)
|Announced||Period||Amount||Yield||Ex-Dividend Date||Record Date||Payable Date|
The Clorox (NYSE CLX) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 1.00%
Institutional Ownership Percentage: 75.69%
The Clorox (NYSE CLX) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|11/28/2017||Michael R Costello||SVP||Sell||10,574||$136.01||$1,438,169.74||34,867|| |
|11/8/2017||Matthew T Laszlo||SVP||Sell||20,051||$130.46||$2,615,853.46||10,896|| |
|8/29/2017||Dawn C. Willoughby||COO||Sell||2,158||$138.00||$297,804.00|| |
|8/23/2017||James E Foster||EVP||Sell||9,861||$138.51||$1,365,847.11||22,069|| |
|8/23/2017||Jon M Balousek||SVP||Sell||9,223||$138.87||$1,280,798.01||20,614|| |
|12/1/2016||A D David Mackay||Director||Buy||5,000||$114.90||$574,500.00|| |
|9/2/2016||Laura Stein||EVP||Sell||38,882||$131.69||$5,120,370.58||48,501|| |
|8/29/2016||Jon M Balousek||SVP||Sell||5,136||$131.14||$673,535.04||15,384|| |
|8/17/2016||Dawn C Willoughby||COO||Sell||10,617||$131.01||$1,390,933.17||20,353|| |
|8/10/2016||Nikolaos A. Vlahos||COO||Sell||925||$133.07||$123,089.75|| |
|5/10/2016||Nikolaos A Vlahos||COO||Sell||2,151||$132.25||$284,469.75||13,883|| |
|2/24/2016||Dawn C Willoughby||COO||Sell||1,550||$129.00||$199,950.00||10,749|| |
|2/8/2016||Nikolaos A. Vlahos||COO||Sell||8,589||$126.60||$1,087,367.40||12,448|| |
|12/7/2015||Jon M Balousek||SVP||Sell||1,488||$128.69||$191,490.72||10,186|| |
|12/4/2015||Jacqueline P Kane||EVP||Sell||852||$127.55||$108,672.60||22,411|| |
|12/3/2015||Thomas D Johnson||VP||Sell||908||$126.09||$114,489.72||13,458|| |
|11/27/2015||Jacqueline P Kane||EVP||Sell||2,160||$125.45||$270,972.00||23,263|| |
|11/25/2015||Thomas D. Johnson||VP||Sell||12,679||$125.04||$1,585,382.16||14,366|| |
|11/19/2015||Laura Stein||EVP||Sell||12,700||$124.42||$1,580,134.00||48,629|| |
|11/17/2015||Stephen Robb||CFO||Sell||30,496||$122.02||$3,721,121.92||24,006|| |
|11/12/2015||James E. Foster||EVP||Sell||5,684||$122.24||$694,812.16||12,787|| |
|11/11/2015||Laura Stein||EVP||Sell||17,577||$124.21||$2,183,239.17||46,582|| |
|11/4/2015||Dawn C. Willoughby||COO||Sell||29,349||$124.06||$3,641,036.94||10,749|| |
|11/4/2015||Laura Stein||EVP||Sell||8,716||$124.50||$1,085,142.00||46,582|| |
|10/6/2015||Stephen Robb||CFO||Sell||19,125||$119.00||$2,275,875.00||22,035|| |
|9/25/2015||Jacqueline P Kane||EVP||Sell||2,340||$115.00||$269,100.00||25,423|| |
|9/25/2015||Stephen Robb||CFO||Sell||21,020||$115.00||$2,417,300.00||20,910|| |
|9/18/2015||Stephen Robb||CFO||Sell||8,500||$113.85||$967,725.00||19,500|| |
|9/17/2015||Jacqueline P Kane||EVP||Sell||5,027||$115.00||$578,105.00||27,573|| |
|9/14/2015||James E. Foster||EVP||Sell||11,999||$109.34||$1,311,970.66||13,287|| |
|9/8/2015||Jon M Balousek||SVP||Sell||1,294||$111.38||$144,125.72||10,733|| |
|9/2/2015||Frank A Tataseo||EVP||Sell||3,673||$110.25||$404,948.25||24,054|| |
|8/28/2015||Thomas D Johnson||VP||Sell||1,051||$111.34||$117,018.34||13,812|| |
|8/27/2015||James E Foster||EVP||Sell||3,000||$111.39||$334,170.00||12,495|| |
|8/20/2015||Nikolaos A Vlahos||COO||Sell||4,800||$116.12||$557,376.00||11,644|| |
|6/16/2015||Jeffrey T Klenda||Director||Buy||394,257||$0.20||$78,851.40|
|3/25/2015||Jeffrey T Klenda||Director||Buy||25,000||$0.16||$3,875.00|
|3/23/2015||Dawn C Willoughby||COO||Sell||5,440||$112.00||$609,280.00|| |
|3/16/2015||Stephen Robb||CFO||Sell||25,279||$109.49||$2,767,797.71|| |
|2/12/2015||Nikolaos A Vlahos||COO||Sell||16,018||$108.01||$1,730,104.18|| |
|2/10/2015||Frank A Tataseo||EVP||Sell||86,087||$107.01||$9,212,169.87|| |
|2/6/2015||Donald R Knauss||Chairman||Sell||272,780||$106.83||$29,141,087.40|| |
|1/9/2015||James E Foster||EVP||Sell||19,048||$106.68||$2,032,040.64|| |
|1/5/2015||Jacqueline P Kane||SVP||Sell||23,534||$103.76||$2,441,887.84|| |
|12/22/2014||Donald R Knauss||Chairman||Sell||270,853||$104.06||$28,184,963.18|| |
|12/8/2014||Nikolaos A Vlahos||COO||Sell||7,394||$99.60||$736,442.40|| |
|11/26/2014||James E Foster||EVP||Sell||15,315||$99.74||$1,527,518.10|| |
|11/26/2014||Thomas D Johnson||VP||Sell||25,006||$99.52||$2,488,597.12|| |
|11/25/2014||Jacqueline P Kane||SVP||Sell||43,430||$99.50||$4,321,285.00|| |
|11/13/2014||Dawn C Willoughby||COO||Sell||4,034||$102.02||$411,548.68|| |
|11/13/2014||Michael R Costello||SVP||Sell||16,348||$102.00||$1,667,496.00|| |
|11/3/2014||George C Roeth||COO||Sell||198,159||$99.46||$19,708,894.14|| |
|9/22/2014||Jacqueline P Kane||SVP||Sell||43,960||$97.00||$4,264,120.00|| |
|8/25/2014||Benno O Dorer||COO||Sell||2,505||$89.12||$223,245.60|| |
|6/9/2014||Thomas D Johnson||VP||Sell||23,737||$89.44||$2,123,037.28|| |
|5/20/2014||Thomas Britanik||CMO||Sell||1,779||$88.48||$157,405.92||11,808|| |
|5/8/2014||Thomas Britanik||CMO||Sell||21,320||$88.00||$1,876,160.00||13,587|| |
|4/29/2014||Wayne Delker||SVP||Sell||14,819||$92.00||$1,363,348.00||13,640|| |
|3/27/2014||Dawn Willoughby||SVP||Sell||2,595||$90.00||$233,550.00||1,864|| |
|12/3/2013||Grant Lamontagne||SVP||Sell||71,860||$93.01||$6,683,698.60||19,736|| |
|11/22/2013||Jon Balousek||SVP||Sell||3,125||$93.72||$292,875.00||6,396|| |
|11/7/2013||Thomas P Britanik||CMO||Sell||5,834||$92.03||$536,903.02|| |
|11/5/2013||Carolyn M Ticknor||Director||Sell||8,000||$90.01||$720,080.00|| |
|10/29/2013||Benno O Dorer||COO||Sell||15,577||$90.25||$1,405,824.25|| |
|10/29/2013||Frank A Tataseo||EVP||Sell||25,200||$90.27||$2,274,804.00|| |
|7/9/2013||Benno O Dorer||COO||Sell||25,714||$85.14||$2,189,289.96|| |
|6/14/2013||Frank A Tataseo||EVP||Sell||1,197||$85.17||$101,948.49|| |
|6/3/2013||Thomas P Britanik||CMO||Sell||2,278||$83.59||$190,418.02|| |
|5/29/2013||Tully M Friedman||Director||Sell||3,000||$84.79||$254,370.00|| |
|5/24/2013||Michael R Costello||VP||Sell||1,217||$85.98||$104,637.66|| |
|5/16/2013||Thomas P Britanik||CMO||Sell||34,258||$87.81||$3,008,194.98|| |
|5/15/2013||George J Harad||Director||Sell||5,497||$87.19||$479,283.43|| |
|5/15/2013||Grant J Lamontagne||SVP||Sell||19,350||$87.62||$1,695,447.00|| |
|5/7/2013||Nikolaos A Vlahos||SVP||Sell||3,769||$86.15||$324,699.35|| |
|2/22/2013||Larry Peiros||COO||Sell||77,200||$83.00||$6,407,600.00|| |
|2/1/2013||Larry Peiros||COO||Sell||10,678||$79.24||$846,124.72|| |
|2/1/2013||Stephen Robb||CFO||Sell||8,781||$79.29||$696,245.49|| |
|12/10/2012||George J Harad||Director||Buy||3,000||$75.95||$227,850.00|| |
|12/4/2012||Laura Stein||SVP||Sell||26,780||$76.34||$2,044,385.20|| |
The Clorox (NYSE CLX) News Headlines
The Clorox (NYSE:CLX) SEC Filings
This page is loading this company's SEC Filings. Please wait...
The Clorox (NYSE:CLX) Income Statement, Balance Sheet and Cash Flow Statement
The Clorox (NYSE CLX) Stock Chart for Tuesday, March, 20, 2018